MoonLake's S-OLARIS Trial Data Shows Positive Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MLTX?
Source: stocktwits
- Clinical Trial Success: MoonLake's S-OLARIS trial demonstrated that 81% of axial spondyloarthritis patients showed significant improvement within 12 weeks, meeting the primary endpoint, indicating Sonelokimab's efficacy in alleviating pain and inflammation, which could lay a strong foundation for the company's future market performance.
- Stable Safety Profile: The trial reported no new safety signals, maintaining consistency with previous studies, which provides confidence for the further development of Sonelokimab and may attract increased investor interest.
- Strong Cash Position: MoonLake reported having $394 million in cash as of 2025, combined with a recent $75 million equity raise, expected to fund operations into the second half of 2027, enhancing the company's capacity for ongoing R&D investments.
- Investor Day Event: MoonLake will host an Investor Day on February 23, discussing outcomes from its FDA meeting and future biologics license application, which is expected to further boost market confidence in the company's prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLTX
Wall Street analysts forecast MLTX stock price to rise
12 Analyst Rating
9 Buy
2 Hold
1 Sell
Moderate Buy
Current: 18.170
Low
5.00
Averages
24.10
High
45.00
Current: 18.170
Low
5.00
Averages
24.10
High
45.00
About MLTX
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MoonLake's S-OLARIS Trial Data Shows Positive Results
- Clinical Trial Success: MoonLake's S-OLARIS trial demonstrated that 81% of axial spondyloarthritis patients showed significant improvement within 12 weeks, meeting the primary endpoint, indicating Sonelokimab's efficacy in alleviating pain and inflammation, which could lay a strong foundation for the company's future market performance.
- Stable Safety Profile: The trial reported no new safety signals, maintaining consistency with previous studies, which provides confidence for the further development of Sonelokimab and may attract increased investor interest.
- Strong Cash Position: MoonLake reported having $394 million in cash as of 2025, combined with a recent $75 million equity raise, expected to fund operations into the second half of 2027, enhancing the company's capacity for ongoing R&D investments.
- Investor Day Event: MoonLake will host an Investor Day on February 23, discussing outcomes from its FDA meeting and future biologics license application, which is expected to further boost market confidence in the company's prospects.
See More
MoonLake's S-OLARIS Trial Results Show Significant Efficacy for Sonelokimab
- Clinical Trial Results: In the S-OLARIS Phase 2 trial, over 81% of axial spondyloarthritis patients achieved an ASAS40 response by Week 12, demonstrating sonelokimab's significant efficacy and suggesting its potential in treating this condition.
- Imaging Improvements: PET/MRI imaging data indicated a significant reduction in inflammation and osteoblast activity in affected joints by Week 12, suggesting a potential disease-modifying effect that could provide better long-term health outcomes for patients.
- Strong Financial Position: As of December 31, 2025, MoonLake reported $394 million in cash and cash equivalents, combined with $75 million from a recent equity raise, expected to fund operations into the second half of 2027, ensuring continued R&D efforts.
- Investor Day Announcement: The company confirmed an Investor Day webcast on February 23, 2026, where it will present S-OLARIS trial data and future plans, further enhancing investor confidence and attracting potential investments.
See More
MoonLake Immunotherapeutics Receives FDA Fast Track Designation for Sonelokimab
- FDA Fast Track Approval: MoonLake recently received FDA Fast Track designation for Sonelokimab in moderate-to-severe palmoplantar pustulosis, which will facilitate more frequent interactions with the FDA, thereby accelerating the drug development process and enhancing market competitiveness.
- Investor Day Catalyst: The company is set to host its Investor Day on February 23, where it will review FDA feedback and its regulatory strategy, expected to provide critical business updates for shareholders that could influence stock price movements.
- Analyst Rating Divergence: While Goldman Sachs downgraded MoonLake to 'Sell' with a $10 price target, analysts from BTIG and H.C. Wainwright expressed optimism, raising their targets to $24 and $32 respectively, indicating differing market perspectives on Sonelokimab's potential.
- Significant Stock Volatility: MLTX shares have gained over 16% in the past three trading sessions but slid slightly in extended trading, reflecting investors' reassessment of potential upside, while the stock remains down 57% over the past year.
See More
Investors Track Economic Data and Fed Minutes for Clarity
- Market Sentiment Shift: Retail sentiment towards the SPDR S&P 500 ETF (SPY) has flipped from 'bearish' to 'bullish' in just one day, indicating a growing confidence among investors that could lead to increased capital inflows in the near term.
- Nvidia Strategic Shift: Nvidia has exited Applied Digital and Arm Holdings while deepening its partnership with Meta by committing to millions of processors, signaling a strategic pivot towards AI and social media that may impact its market share and competitive positioning.
- Tesla Compliance Action: Tesla has avoided a 30-day sales suspension in California after taking 'corrective action' in the marketing of its Autopilot and Full Self-Driving features, which will help maintain its brand image and market position.
- Economic Data Focus: Investors are closely watching the release of housing starts at 8:30 AM ET and industrial production data at 9:15 AM, as these figures will provide crucial signals about economic health that could influence the Federal Reserve's monetary policy decisions.
See More
Cormorant Increases MoonLake Stake Above 6%
- Stake Increase: Cormorant Asset Management disclosed on Tuesday that it has increased its stake in MoonLake Immunotherapeutics to 4.36 million shares, representing a 6.1% ownership, up from about 2 million shares in October 2025, indicating strong confidence in the company's future and potential stock price impact.
- Significant Stock Surge: Following the news of Cormorant's increased stake, MoonLake's shares jumped 11% on Tuesday, marking the largest rally in over a month, reflecting heightened market interest in a possible takeover and potentially attracting more investors.
- Market Sentiment Shift: Retail sentiment for MLTX on Stocktwits flipped from 'extremely bearish' to 'extremely bullish' with a 900% surge in message volume over 24 hours, indicating strong investor expectations for the company's future, which could further drive stock price increases.
- FDA Fast Track Progress: MoonLake's Sonelokimab received FDA Fast Track designation, with plans to pursue a biologics license application in the second half of 2026, highlighting the company's potential in the treatment space and likely drawing increased institutional investor interest in its long-term growth prospects.
See More
Merck Seeks Acquisitions to Strengthen Drug Portfolio
- Portfolio Strengthening: Merck is actively seeking acquisitions to bolster its drug portfolio, particularly as its blockbuster cancer therapy Keytruda is set to lose patent protection in 2028, with Keytruda generating approximately $29.5 billion in global sales for 2024, accounting for 46% of the company's total sales.
- Acquisition Attempts Fail: Although Merck considered acquiring cancer drugmaker Revolution Medicines for about $30 billion in January, the deal fell through due to a failure to agree on price, highlighting the intense competition in the pharmaceutical market.
- MoonLake Developments: Switzerland-based MoonLake Therapeutics is developing sonelokimab for inflammatory diseases, with the FDA granting Fast Track designation for moderate-to-severe palmoplantar pustulosis this month, and the company plans to apply for approval in hidradenitis suppurativa in the second half of 2026.
- Investor Sentiment Shift: Despite MLTX stock dropping 59% this year, retail investor sentiment has improved amid buyout speculation, with shares closing 11% higher in regular trading, indicating a growing optimism about potential acquisition opportunities.
See More
MoonLake's S-OLARIS Trial Data Shows Positive Results
- Clinical Trial Success: MoonLake's S-OLARIS trial demonstrated that 81% of axial spondyloarthritis patients showed significant improvement within 12 weeks, meeting the primary endpoint, indicating Sonelokimab's efficacy in alleviating pain and inflammation, which could lay a strong foundation for the company's future market performance.
- Stable Safety Profile: The trial reported no new safety signals, maintaining consistency with previous studies, which provides confidence for the further development of Sonelokimab and may attract increased investor interest.
- Strong Cash Position: MoonLake reported having $394 million in cash as of 2025, combined with a recent $75 million equity raise, expected to fund operations into the second half of 2027, enhancing the company's capacity for ongoing R&D investments.
- Investor Day Event: MoonLake will host an Investor Day on February 23, discussing outcomes from its FDA meeting and future biologics license application, which is expected to further boost market confidence in the company's prospects.
See More
MoonLake's S-OLARIS Trial Results Show Significant Efficacy for Sonelokimab
- Clinical Trial Results: In the S-OLARIS Phase 2 trial, over 81% of axial spondyloarthritis patients achieved an ASAS40 response by Week 12, demonstrating sonelokimab's significant efficacy and suggesting its potential in treating this condition.
- Imaging Improvements: PET/MRI imaging data indicated a significant reduction in inflammation and osteoblast activity in affected joints by Week 12, suggesting a potential disease-modifying effect that could provide better long-term health outcomes for patients.
- Strong Financial Position: As of December 31, 2025, MoonLake reported $394 million in cash and cash equivalents, combined with $75 million from a recent equity raise, expected to fund operations into the second half of 2027, ensuring continued R&D efforts.
- Investor Day Announcement: The company confirmed an Investor Day webcast on February 23, 2026, where it will present S-OLARIS trial data and future plans, further enhancing investor confidence and attracting potential investments.
See More
MoonLake Immunotherapeutics Receives FDA Fast Track Designation for Sonelokimab
- FDA Fast Track Approval: MoonLake recently received FDA Fast Track designation for Sonelokimab in moderate-to-severe palmoplantar pustulosis, which will facilitate more frequent interactions with the FDA, thereby accelerating the drug development process and enhancing market competitiveness.
- Investor Day Catalyst: The company is set to host its Investor Day on February 23, where it will review FDA feedback and its regulatory strategy, expected to provide critical business updates for shareholders that could influence stock price movements.
- Analyst Rating Divergence: While Goldman Sachs downgraded MoonLake to 'Sell' with a $10 price target, analysts from BTIG and H.C. Wainwright expressed optimism, raising their targets to $24 and $32 respectively, indicating differing market perspectives on Sonelokimab's potential.
- Significant Stock Volatility: MLTX shares have gained over 16% in the past three trading sessions but slid slightly in extended trading, reflecting investors' reassessment of potential upside, while the stock remains down 57% over the past year.
See More
Investors Track Economic Data and Fed Minutes for Clarity
- Market Sentiment Shift: Retail sentiment towards the SPDR S&P 500 ETF (SPY) has flipped from 'bearish' to 'bullish' in just one day, indicating a growing confidence among investors that could lead to increased capital inflows in the near term.
- Nvidia Strategic Shift: Nvidia has exited Applied Digital and Arm Holdings while deepening its partnership with Meta by committing to millions of processors, signaling a strategic pivot towards AI and social media that may impact its market share and competitive positioning.
- Tesla Compliance Action: Tesla has avoided a 30-day sales suspension in California after taking 'corrective action' in the marketing of its Autopilot and Full Self-Driving features, which will help maintain its brand image and market position.
- Economic Data Focus: Investors are closely watching the release of housing starts at 8:30 AM ET and industrial production data at 9:15 AM, as these figures will provide crucial signals about economic health that could influence the Federal Reserve's monetary policy decisions.
See More
Cormorant Increases MoonLake Stake Above 6%
- Stake Increase: Cormorant Asset Management disclosed on Tuesday that it has increased its stake in MoonLake Immunotherapeutics to 4.36 million shares, representing a 6.1% ownership, up from about 2 million shares in October 2025, indicating strong confidence in the company's future and potential stock price impact.
- Significant Stock Surge: Following the news of Cormorant's increased stake, MoonLake's shares jumped 11% on Tuesday, marking the largest rally in over a month, reflecting heightened market interest in a possible takeover and potentially attracting more investors.
- Market Sentiment Shift: Retail sentiment for MLTX on Stocktwits flipped from 'extremely bearish' to 'extremely bullish' with a 900% surge in message volume over 24 hours, indicating strong investor expectations for the company's future, which could further drive stock price increases.
- FDA Fast Track Progress: MoonLake's Sonelokimab received FDA Fast Track designation, with plans to pursue a biologics license application in the second half of 2026, highlighting the company's potential in the treatment space and likely drawing increased institutional investor interest in its long-term growth prospects.
See More
Merck Seeks Acquisitions to Strengthen Drug Portfolio
- Portfolio Strengthening: Merck is actively seeking acquisitions to bolster its drug portfolio, particularly as its blockbuster cancer therapy Keytruda is set to lose patent protection in 2028, with Keytruda generating approximately $29.5 billion in global sales for 2024, accounting for 46% of the company's total sales.
- Acquisition Attempts Fail: Although Merck considered acquiring cancer drugmaker Revolution Medicines for about $30 billion in January, the deal fell through due to a failure to agree on price, highlighting the intense competition in the pharmaceutical market.
- MoonLake Developments: Switzerland-based MoonLake Therapeutics is developing sonelokimab for inflammatory diseases, with the FDA granting Fast Track designation for moderate-to-severe palmoplantar pustulosis this month, and the company plans to apply for approval in hidradenitis suppurativa in the second half of 2026.
- Investor Sentiment Shift: Despite MLTX stock dropping 59% this year, retail investor sentiment has improved amid buyout speculation, with shares closing 11% higher in regular trading, indicating a growing optimism about potential acquisition opportunities.
See More
